FDA's Scott Got­tlieb is field­ing a new team of re­cruiters to start scout­ing top tal­ent

Biotech ex­ecs have been bull­ish sup­port­ers of the FDA in re­cent years, of­fer­ing their ap­pre­ci­a­tion of faster re­view times with new pro­grams like the break­through ther­a­py des­ig­na­tion. But if there’s one re­cur­rent gripe you hear fre­quent­ly, it’s that the reg­u­la­tors bio­phar­ma com­pa­nies and pa­tient ad­vo­cates deal with don’t have the right kind of sci­en­tif­ic ex­pe­ri­ence for the drugs un­der re­view — es­pe­cial­ly as you stray out­side of on­col­o­gy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER